Atara Biotherapeutics, Inc. |
Director |
Common Stock |
630K |
$453K |
$0.72 |
Mar 31, 2024 |
Direct |
Certara, Inc. |
Director |
Common Stock |
7.06K |
$127K |
$18.00 |
Jun 15, 2021 |
Direct |
Atara Biotherapeutics, Inc. |
Director |
Non-Qualified Stock Option (Right to Buy) |
79.5K |
|
|
May 31, 2023 |
Direct |
PMV Pharmaceuticals, Inc. |
Director |
Stock Option (right to buy) |
67.5K |
|
|
Jun 7, 2024 |
Indirect |
Frazier Lifesciences Acquisition Corp |
Director |
Class B Ordinary Shares |
0 |
|
|
Nov 22, 2022 |
Direct |
Mirati Therapeutics, Inc. |
Director |
Common Stock |
0 |
|
$59.02 |
Jan 23, 2024 |
Direct |
Mirati Therapeutics, Inc. |
Director |
Option to Purchase Common Stock |
0 |
|
|
Jan 23, 2024 |
Direct |
PMV Pharmaceuticals, Inc. |
Director |
Stock Option (right to buy) |
0 |
|
|
Jun 7, 2024 |
Direct |
Turning Point Therapeutics, Inc. |
Director |
Stock Option (right to buy) |
0 |
|
|
Aug 17, 2022 |
By the Gallagher Revocable Trust dated May 10, 2011 |
Turning Point Therapeutics, Inc. |
Director |
Stock Option (right to buy) |
0 |
|
|
Aug 17, 2022 |
Direct |